Next Article in Journal
Comparative Analysis of Serum (Anti)oxidative Status ParŠ°meters in Healthy Persons
Next Article in Special Issue
The Molecular Fingerprint of High Grade Serous Ovarian Cancer Reflects Its Fallopian Tube Origin
Previous Article in Journal
Early Exercise Protects against Cerebral Ischemic Injury through Inhibiting Neuron Apoptosis in Cortex in Rats
Previous Article in Special Issue
A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies
Int. J. Mol. Sci. 2013, 14(3), 6090-6105; doi:10.3390/ijms14036090

PAX2 Expression in Ovarian Cancer

, 1,2
, 1,2
, 1
, 1
, 1
, 1
, 1,2
, 1
 and 1,2,*
Received: 25 January 2013 / Revised: 5 March 2013 / Accepted: 13 March 2013 / Published: 15 March 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
View Full-Text   |   Download PDF [1539 KB, updated 19 June 2014; original version uploaded 19 June 2014]   |   Browse Figures
Abstract: PAX2 is one of nine PAX genes that regulate tissue development and cellular differentiation in embryos. However, the functional role of PAX2 in ovarian cancer is not known. Twenty-six ovarian cancer cell lines with different histology origins were screened for PAX2 expression. Two ovarian cancer cell lines: RMUGL (mucinous) and TOV21G (clear cell), with high PAX2 expression were chosen for further study. Knockdown PAX2 expression in these cell lines was achieved by lentiviral shRNAs targeting the PAX2 gene. PAX2 stable knockdown cells were characterized for cell proliferation, migration, apoptosis, protein profiles, and gene expression profiles. The result indicated that these stable PAX2 knockdown cells had reduced cell proliferation and migration. Microarray analysis indicated that several genes involved in growth inhibition and motility, such as G0S2, GREM1, and WFDC1, were up-regulated in PAX2 knockdown cells. On the other hand, over-expressing PAX2 in PAX2-negative ovarian cell lines suppressed their cell proliferation. In summary, PAX2 could have both oncogenic and tumor suppression functions, which might depend on the genetic content of the ovarian cancer cells. Further investigation of PAX2 in tumor suppression and mortality is warranty.
Keywords: PAX2; ovarian cancer; G0S2; WFDC1; GREM1; shRNA PAX2; ovarian cancer; G0S2; WFDC1; GREM1; shRNA
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |

MDPI and ACS Style

Song, H.; Kwan, S.-Y.; Izaguirre, D.I.; Zu, Z.; Tsang, Y.T.; Tung, C.S.; King, E.R.; Mok, S.C.; Gershenson, D.M.; Wong, K.-K. PAX2 Expression in Ovarian Cancer. Int. J. Mol. Sci. 2013, 14, 6090-6105.

AMA Style

Song H, Kwan S-Y, Izaguirre DI, Zu Z, Tsang YT, Tung CS, King ER, Mok SC, Gershenson DM, Wong K-K. PAX2 Expression in Ovarian Cancer. International Journal of Molecular Sciences. 2013; 14(3):6090-6105.

Chicago/Turabian Style

Song, Huijuan; Kwan, Suet-Yan; Izaguirre, Daisy I.; Zu, Zhifei; Tsang, Yvonne T.; Tung, Celestine S.; King, Erin R.; Mok, Samuel C.; Gershenson, David M.; Wong, Kwong-Kwok. 2013. "PAX2 Expression in Ovarian Cancer." Int. J. Mol. Sci. 14, no. 3: 6090-6105.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert